ALB and non-small cell lung carcinoma: Therefore, we validated the independent potential markers after treatment with a previously defined cutoff, PLR [ ≤ 168.13 (n = 23) vs. >168.13 (n = 24)] and albumin [ ≤ 43 g/L (n = 27) vs. >43 g/L (n = 18)], in NSCLC patients treated with nivolumab.